Posts by tag
ESMO
Sustainability, the Architecture of Equitable Cancer Innovation
In oncology today, innovation advances at a breathtaking pace, yet the capacity to deliver it to all who need it lags behind. Each new therapeutic frontier exposes the same paradox: the deeper our biological insight becomes, the wider the gulf…
Common Sense Oncology: Putting Patients Back at the Center in the Era of Cancer Innovation
Precision medicine, immunotherapy, and cellular therapies have reshaped the landscape of oncology, turning once-fatal diagnoses into chronic, or even curable, conditions. These breakthroughs represent extraordinary scientific progress and a deepening understanding of cancer biology. Yet beneath this success runs a…
ESMO provides first recommendations on use of next-generation sequencing in metastatic cancer
Patients with metastatic non-squamous non-small-cell lung cancer (NSCLC), prostate cancers, ovarian cancers and cholangiocarcinoma should be offered next-generation sequencing (NGS) for profiling tumour samples, concludes an expert panel from the European Society for Medical Oncology (ESMO) in their review (Mosele…
Cancer drugs, costs and clinical benefits are not aligned
According to an international study just published in Lancet Oncology, the cost of new cancer drugs is not associated to the clinical value of the therapy: “In the USA and European countries, prices of cancer drugs should be better aligned…
Covid-19 pandemic: information and resources to support the cancer care community
As soon as the first analysis of the risk for severe COVID-19 in patients with cancer was published online in Lancet Oncology on February 14th, 2020, it emerged that these patients might have a higher risk of COVID-19 compared to…